GlassScriptPhysician profile
Andrew Newman
NPI 1386091163
$2,869.55
in general payments reported to CMS, 2019-2025
21 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $86.65 · 2021: $320 · 2022: $143 · 2023: $520 · 2024: $349 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496 · Education: $85.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.52 |
| Education | $85.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,043.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $388.07 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $318.25 | 2019-2025 | |
| Janssen Biotech, INC. | $249.93 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $165.00 | 2019-2023 | |
| Lilly USA, LLC | $159.32 | 2019-2024 | Olumiant, Taltz |
| Leo Pharma INC. | $137.82 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $51.75 | 2021-2023 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.11 | 2021-2024 | Duobrii, Siliq |
| Novartis Pharmaceuticals Corporation | $38.85 | 2023-2024 | |
| Incyte Corporation | $34.43 | 2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $32.54 | 2024-2025 | Zoryve |
| Kyowa Kirin, INC. | $29.96 | 2023 | Poteligeo |
| Hill Dermaceuticals, INC. | $29.73 | 2025 | Tolak |
| E.R. Squibb & Sons, L.L.C. | $26.47 | 2023 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.85 | 2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.83 | 2023 | Cyltezo |
| Phadia US INC. | $19.61 | 2023 | Immunocap |
| Ucb, INC. | $17.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.98 | 2019 | |
| Botanix Sb INC | $15.06 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.